Door-to-door tuberculosis (TB) screening and contact tracing can improve diagnosis rates, but must be paired with effective follow-up care to be successful, a new Cochrane Review has found.

-- A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis
-- Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries
-- The M72/AS01E vaccine candidate could be the first new TB vaccine in 100 years if proven effective

Radiant Moms is a study that aims to explore the feasibility, acceptability, and perceived demand for the new 17-week RPT-MOX regimen (rifapentine, moxifloxacin, isoniazid and pyrazinamide) for pregnant and breastfeeding women among key stakeholders. The study has been approved by the Columbia University Irving Medical Center Institutional Review Board in the U.S. and the Stellenbosch University Research Ethics Committee in South Africa, as a collaborative project.

The Secretariat of the Global Laboratory Initiative (GLI) of the Stop TB Partnership, that is hosted by the World Health Organization Global TB Program announced a call for applications for a new member specifically representing communities and persons affected by TB, to serve on the GLI Core Group in 2024-2026.

Public Health Action is the peer-reviewed open access journal of The International Union Against Tuberculosis and Lung Disease. It communicates and reports new knowledge across all relevant areas of operational research including: infection control, nutrition, TB, HIV, vaccines, smoking, COVID-19, microbial resistance and disease outbreaks.

Global tuberculosis (TB) incidence, mortality, and disability-adjusted life years (DALYs) have decreased significantly in adolescents and young adults since 1990, but the incidence of drug-resistant TB increased, Chinese researchers reported in Pediatrics.

Treatment Action Group (TAG) released an overview of TB research data reported at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held on 3-6 March 2024 in Denver, Colorado, USA.

Community Connect, an open-access space, is a valuable addition and important highlight of The Union World Conference of Lung Health 2024. This year’s program will comprise of sessions in 4 tracks.

The World Health Organization (WHO) has coordinated the selection of new members to the WHO Civil Society Task Force on Tuberculosis (CSTF-TB) for the period 2024 - 2025. Building on achievements of the CSTF-TB to date, the Task Force will continue to serve as a platform for discussion and exchange with WHO, advising WHO on leveraging engagement with civil society and affected communities at all levels to implement the Guidance on engagement of communities and civil society to end tuberculosis and accelerate progress towards ending TB.

WASHINGTON, March 14, 2024 -- A new tuberculosis (TB) test disclosed in the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) Clinical Chemistry journal would allow testing for TB treatment monitoring to occur outside of a biosafety level 3 (BSL-3) laboratory. This could help reduce worldwide mortality from TB by enabling low- and middle-income countries that lack BSL-3 facilities to treat TB more efficiently.